Screener
Supernus Pharmaceuticals SUPN Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued product returns and rebates | 189,720 | 161,097 |
| Contingent consideration, current portion | — | 31,052 |
| Other current liabilities | 82,965 | 38,222 |
| Total current liabilities | 373,929 | 338,171 |
| Contingent consideration, long-term | 206 | 206 |
| Operating lease liabilities, long-term | 30,267 | 30,365 |
| Other liabilities | 19,518 | 22,192 |
| Total liabilities | 423,920 | 390,934 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's total current liabilities?
- Supernus Pharmaceuticals (SUPN) reported total current liabilities of $373.93M in Q1 2026.
- How has Supernus Pharmaceuticals's total current liabilities changed year-over-year?
- Supernus Pharmaceuticals's total current liabilities increased by 32.7% year-over-year, from $281.77M to $373.93M.
- What is the long-term trend for Supernus Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's total current liabilities has grown at a 6.6% compound annual growth rate (CAGR), from $245.11M to $338.17M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Supernus Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude